New lifestyle drugs and somatoform disorders in dermatology

Journal of the European Academy of Dermatology and Venereology

Volumn 22, Issue 2, 2008, Pages 141-149

  Harth, W ^a   Seikowski, K ^b   Hermes, B ^a   Gieler, U ^c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Body dysmorphic disorder; Botulinum toxin; Hypochondria; Isotretinoin; Lifestyle drugs; Somatoform

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; APOMORPHINE; ATOMOXETINE; BOTULINUM TOXIN; DESIPRAMINE; DONEPEZIL; FINASTERIDE; FLUOXETINE; GROWTH HORMONE; ISOTRETINOIN; LATANOPROST; METFORMIN; METHYLPHENIDATE; MINOXIDIL; MODAFINIL; N ACETYLNORLEUCYLASPARTYLHISTIDYL DEXTRO PHENYLALANYLARGINYLTRYPTOPHYLLYSINE 2,7 CYCLIC AMIDE; NOOTROPIC AGENT; PHENTOLAMINE; PHOSPHODIESTERASE INHIBITOR; ROSUVASTATIN; SIBUTRAMINE; SILDENAFIL; SIMVASTATIN; TADALAFIL; TESTOSTERONE; TETRAHYDROLIPSTATIN; UNINDEXED DRUG; VARDENAFIL;

ALERTNESS; ALTERNATIVE MEDICINE; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BODY DYSMORPHIC DISORDER; BREAST; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; CUTANEOUS PARAMETERS; DERMATOLOGY; DOCTOR PATIENT RELATION; DRUG ABUSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EMOTIONAL DISORDER; ERECTILE DYSFUNCTION; FECES INCONTINENCE; FEMALE SEXUAL DYSFUNCTION; FLATULENCE; HAIR LOSS; HUMAN; HYPOCHONDRIASIS; INTELLECT; LEARNING; LIBIDO; LOW DRUG DOSE; MALE TYPE ALOPECIA; MEMORY; MENOPAUSAL SYNDROME; MENTAL FUNCTION; METABOLIC DISORDER; MORTALITY; NARCOLEPSY; NEUROPATHY; NUTRIENT SUPPLY; OBESITY; PAIN; PRIORITY JOURNAL; PSYCHOPATHY; PSYCHOPHARMACOLOGY; QUALITY OF LIFE; REVIEW; SEBORRHEA; SEXUAL AROUSAL DISORDER; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SIDE EFFECT; SKIN PIGMENTATION; SOCIAL LIFE; SOCIAL MEDICINE; SOMATIZATION; SOMATOFORM DISORDER; TERATOGENICITY; VITAMIN SUPPLEMENTATION; WAKEFULNESS; WEIGHT REDUCTION; WELLBEING; WRINKLE;

AGING; COSMETICS; ESTHETICS; HUMANS; LIFE STYLE; PSYCHOLOGY; PSYCHOTHERAPY; SKIN CARE; SOMATOFORM DISORDERS;

EID: 38349014807     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2007.02507.x     Document Type: Review

References (68)

1. Lexchin J. Lifestyle drugs: Issues for debate. CMAJ 2001; 15: 1449-1451.
2. Miller AR. Lifestyle drugs. CMAJ 2001; 24: 153.
3. Flower R. Lifestyle drugs: Pharmacology and the social agenda. Trends Pharmacol Sci 2004; 25: 182-185.
4. Moldrup C. The use of the terms 'lifestyle medicines'or 'lifestyle drugs'. Pharm World Sci 2004; 26: 193-196.
5. Coons SJ, Motheral BR. Quality-of-Life drugs? Clin Ther 2000; 22: 773-774.
6. Young SN. Lifestyle drugs, mood, behaviour and cognition. J Psychiatry Neurosci 2003; 28: 87-89.
7. Mbongue TB, Sommet A, Pathak A, Montastruc JL. 'Medicamentation'of society, non-diseases and non-medications: A point of view from social pharmacology. Eur J Clin Pharmacol 2005; 61: 309-313.
8. Harth W, Gieler U. Psychosomatische Dermatologie. Springer Medizin Verlag, Heidelberg, 2006.
9. Brosig B, Kupfer J, Niemeier V, Gieler U. The Dorian Gray Syndrome: psychodynamic need for hair growth restorers and other fountains of youth. Int J Clin Pharmacol Ther 2001; 39: 279-283.
10. Hesselink JM. Surfen mit Nebenwirkungen. Probleme rund um die Smartdrugs. Dtsch Med Wochenschr 1999; 124: 707-710.
11. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-581.
12. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. J Am Coll Health 2005; 53: 253-262.
13. Ashton H. The diagnosis and management of benzodiazepine dependence. Curr Opin Psychiatry 2005; 18: 249-255.
14. Kruszewski SP. Euphorigenic and abusive properties of modafinil. Am J Psychiatry 2006; 163: 549.
15. Pelissier-Alicot AL, Piercecchi-Marti MD, Bartoli C et al. Abusive prescription of psychostimulants: A study of two cases. J Forensic Sci 2006; 51: 407-410.
16. Knopman DS. Current treatment of mild cognitive impairment and Alzheimer's disase. Curr Neurol Neurosci Rep 2006; 6: 365-371.
17. Claret L, Cox EH, McFadyen L et al. Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra). Pharm Res 2006; 23: 1756-1764.
18. Hengeveld MW. Somatization of erectile disorders by the introduction of sildenafil. Ned Tijdschr Geneeskd 1998; 142: 2333-2336.
19. Bella AJ, Brant WO, Lue TF, Brock GB. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can J Urol 2006; 13: 3233-3238.
20. Kohn FM. Testosterone and body functions. Aging Male 2006; 9: 183-188.
21. Morales A, Nieschlag E, Schubert M, Yassin AA, Zitzmann M, Oettel M. Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male 2006; 9: 221-227.
22. Simon J, Braunstein G, Nachtigall L et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90: 5226-5233.
23. Seftel A. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. J Urol 2005; 173: 1279-1280.
24. Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006; 3: 628-638.
25. Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology 2005; 65: 755-759.
26. Van der Lely AJ. Hormone use and abuse: What is the difference between hormones as fountain of youth nd doping in sports? J Endocrinol Invest 2003; 26: 932-936.
27. Bozzola E, Giacchero R, Barberi S, Borroni G. Sutton's nevus and growth hormone therapy. Minerva Pediatr 2004; 56: 349-351.
28. Liebel FP, Zimmermann E. 1-diabetes - causes, pathogenesis and therapy. Med Hypotheses 2006; 67: 493-505.
29. Darwin M, Schanzer S, Teichmann A, Blume-Peytavi U, Sterry W, Lademann J. Functional food and bioavailability in the target organ skin. Hautarzt 2006; 57: 286-290.
30. Schmidt JB. Neue Aspekte der Prophylaxe und Therapie des Hautalterns. In: Plettenberg A, Meigel WN, Moll I, eds. Dermatologie an der Schwelle zum neuen Jahrtausend. Aktueller Stand Von Klinik und Forschung. Springer Verlag, Heidelberg, 2000.
31. Geissler SE, Michelsen S, Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges 2003; 1: 952-958.
32. Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin Pharmacother 2004; 5: 933-940.
33. Olsen EA, Hordinsky M, Whiting D et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55: 1014-1023.
34. Harth W, Linse R. Botulinophilia: Contraindication for therapy with botulinum toxin. Int J Clin Pharmacol Ther 2001; 39: 460-463.
35. Hinz A, Brähler E, Brosig B, Stirn A. Verbreitung von Körperschmuck und Inanspruchnahme von Lifestyle-Medizin in Deutschland. BZGA Forum Sexualaufklärung und Familienplanung 2006; 1: 7-11.
36. Kadison R. Getting an edge - use of stimulants and antidepressants in college. N Engl J Med 2005; 353: 1089-1091.
37. Striegel H, Simon P, Frisch S et al. Anabolic ergogenic substance users in fitness-sports: A distinct group supported by the health care system. Drug Alcohol Depend 2006; 81: 11-19.
38. Gesellschaft für ästhetische Chirurgie Deutschland. Top 10 der Schönheitsoperationen. Pressemitteilung via Int (1.3.2007). http://www.dgac.de.
39. Ashworth M, Clement S, Wright M. Demand, appropriateness and prescribing of 'lifestyle drugs': A consultation survey in general practice. Fam Pract 2002; 19: 236-241.
40. Beck D. Das Koryphäen-Killer-Syndrom. Dtsch Med Wschr 1977; 102: 303-307.
41. Harth W, Linse R. Body dysmorphic disorder and life-style drugs. Overview and case report with finasteride. Int J Clin Pharmacol Ther 2001; 39: 284-287.
42. Phillips KA, Grant J, Siniscalchi J, Albertini RS. Surgical and nonpsychiatric medical treatment of patients with body dysmorphic disorder. Psychosomatics 2001; 42: 504-510.
43. Sass H, Wittchen HU, Zaudig M. Diagnostisches und Statistisches Manual Psychischer Störungen DSM-IV. Hogrefe Verlag für Psychologie, Berlin Toronto Seattle, 2001.
44. Weltgesundheitsorganisation. ICD-10- Internationale Statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme. 10. Revision, Band 1. Ärzte Verlag, Köln. Deutscher, 1995.
45. Stangier U, Gieler U. Somatoforme Störungen in der Dermatologie. Psychotherapie 1997; 2: 91-101.
46. Cotterill JA. Body dysmorphic disorder. Dermatol Clin 1996; 14: 457-463.
47. Phillips KA, Menard W. Suicidality in body dysmorphic disorder. a prospective study. Am J Psychiatry 2006; 163: 1280-1282.
48. Rief W, Buhlmann U, Wilhelm S, Borkenhagen A, Brahler E. The prevalence of body dysmorphic disorder: A population-based survey. Psychol Med 2006; 36: 877-885.
49. Bohne A, Keuthen NJ, Wilhelm S, Deckersbach T, Jenike MA. Prevalence of symptoms of body dysmorphic disorder and its correlates: A cross-cultural comparison. Psychosomatics 2002; 43: 486-490.
50. Phillips KA, Dufresne RG, Wilkel CS, Vittorio CC. Rate of body dysmorphic disorder in dermatology patients. J Am Acad Dermatol 2000; 42: 436-441.
51. Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol 2006; 21: 177-179.
52. Cash TF. The psychological effects of androgenetic alopecia in men. J Am Acad Dermatol 1992; 26: 926-931.
53. Pope CG, Pope HG, Menard W, Fay C, Olivardia R, Phillips KA. Clinical features of muscle dysmorphia among males with body dysmorphic disorder. Body Image 2005; 2: 395-400.
54. Grant JE, Menard W, Pagano ME, Fay C, Phillips KA. Substance use disorders in individuals with body dysmorphic disorder. J Clin Psychiatry 2005; 66: 309-316.
55. Kanayama G, Barry S, Hudson JI, Pope HG Jr. Body image and attitudes toward male roles in anabolic-androgenic steroid users. Am J Psychiatry 2006; 163: 697-703.
56. Krogstad AL, Mork C, Piechnik SK. Daily pattern of sweating and response to stress and exercise in patients with palmar hyperhidrosis. Br J Dermatol 2006; 154: 1118-1122.
57. Sciuchetti JF, Ballabio D, Corti F et al. Endoscopic thoracic sympathectomy by camping in the treatment of social phobia: The Monza experience. Minerva Chir 2006; 61: 417-420.
58. De Jong PJ, Peters ML. Do blushing phobics overestimate the undesirable communicative effects of their blushing? Behav Res Ther 2005; 43: 747-758.
59. Luzzi GA. Chronic prostatitis and chronic pelvic pain in men: Aetiology, diagnosis and management. J Eur Acad Dermatol Venereol 2002; 16: 253-256.
60. Niemeier V, Kupfer J, Harth W et al. Sind Patienten mit Glossodynie psychisch unauffällig? Eine psychodiagnostisch schwer fassbare Erkrankung. Psychother Psych Med Psychologie 2002; 52: 425-432.
61. Kivanc-Altunay I, Savas C, Gokdemir G, Koslu A, Ayaydin EB. The presence of trichodynia in patients with telogen effluvium and androgenetic alopecia. Int J Dermatol 2003; 42: 691-693.
62. Reissman D. The pros and cons of covering lifestyle drugs. Dis Manage Health Outcomes 1999; 6: 249-251.
63. Washeim HA, Moesler TA. Dysmorphophobia - a disorder of modern times? Fortschr Med 1995; 113: 349-350.
64. Woodruff P, Higgins E, du Vivier A, Wessely S. Psychiatric illness in patients referred to a dermatology-psychiatry clinic. Gen Hosp Psychiatry 1997; 19: 29-35.
65. McKay D. Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder. Behav Modif 1999; 23: 620-629.
66. Wilhelm S, Otto MW, Lohr B, Deckersbach T. Cognitive behavior group therapy for body dysmorphic disorder: A case series. Behav Res Ther 1999; 37: 71-75.
67. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 2002; 59: 381-388.
68. Hollander E, Allen A, Kwon J et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 1999; 56: 1033-1039.